MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma
15 Novembre 2022 - 2:00PM
Business Wire
Novel anticancer agent may enhance overall
therapeutic efficacy of current immune checkpoint inhibitor-based
treatments
MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the
Company”), a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer, today announced the results of
a pre-clinical study of the Company’s lead drug candidate, THIO, in
hepatocellular carcinoma (HCC) in vitro and in vivo models. MAIA
presented the data at the Society for Immunotherapy of Cancer’s
(SITC) 37th Annual Meeting, held Nov. 8-12 virtually and in
Boston.
The results indicate that THIO, a first-in-class
telomere-targeted agent may enhance the overall therapeutic
efficacy of current immune checkpoint inhibitor-based treatments
for HCC. In April, MAIA received an Orphan Drug Designation from
the U.S. Food and Drug Administration (FDA) for THIO for the
treatment of HCC.
Before the study, the researchers hypothesized that
telomere-targeting agents may be effective in HCC. The study
evaluated the activity of THIO and second-generation analogues in
vitro using telomerase-positive HCC cells and in vivo using
syngeneic mouse models of aggressive HCC.
The study found that THIO treatment:
- Directly killed cancer cells, as it induced replicative stress,
followed by cell cycle arrest and apoptosis in
telomerase-reactivated HCC cells.
- Stimulated anti-tumor immune response, as it activated pathways
associated with innate and adaptive immunity and altered the
immune-suppressive tumor microenvironment in syngeneic mouse models
of aggressive HCC.
- Enhanced the response to immune therapy checkpoint inhibitors,
yielding complete responses in some HCC model systems with no
dose-limiting toxicities.
“In addition to observing complete responses with no recurrence
after THIO treatment, we identified immune memory, meaning that the
body was able to autonomously target cancer cells when challenged
with an influx of even more cancer cells,” said MAIA Chairman and
Chief Executive Officer Vlad Vitoc, M.D. “We are thrilled with this
latest set of data as all models treated with THIO exhibited
curative properties. The projected growth of liver cancer cases
illustrates an increasing unmet global medical need for effective
HCC therapies and this latest data reaffirms our belief in THIO’s
potential to address it. We also strongly believe that the U.S.
FDA’s Orphan Drug Designation of THIO for HCC further validates the
quality of our data, and we look forward to continuing its clinical
development.”
About the SITC 37th Annual Meeting
The SITC 37th Annual Meeting provides a multidisciplinary
educational and interactive environment focused on improving the
outcome for current and future patients with cancer by
incorporating strategies based on basic and applied cancer
immunotherapy. The Annual Meeting consists of cutting-edge research
presentations by experts in the field, oral and poster abstract
presentations and ample opportunity for structured and informal
discussions, including important networking opportunities. In
addition, the meeting includes updates on major national and
international initiatives coming from academia, government and
industry, as well as important society projects. Additional meeting
information is available on SITC's website.
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a
telomere-targeting agent currently in clinical development to
evaluate its activity in non-small cell lung cancer (NSCLC), in
sequential administration with cemiplimab (Libtayo®),
a PD-1 inhibitor developed by Regeneron. Telomeres play a
fundamental role in the survival of cancer cells and their
resistance to current therapies. THIO is being developed as a
second or higher line of treatment for NSCLC for patients that have
progressed beyond the standard-of-care regimen of existing
checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer. The Company’s lead program is
THIO, a potential first-in-class cancer telomere targeting agent in
clinical development for the treatment of patients with
telomerase-positive cancers. For more information, please visit
www.maiabiotech.com.
Forward Looking Statements
This press release includes forward-looking statements
including, but not limited to, statements related to the closing of
the offering and the expected use of proceeds, development of drug
candidates, our operations and business strategy, our expected
financial results, and corporate updates. The forward-looking
statements contained in this press release are based on
management’s current expectations and are subject to substantial
risks, uncertainty and changes in circumstances. Actual results may
differ materially from those expressed by these expectations due to
risks and uncertainties, including, among others, those related to
our ability to obtain additional capital on favorable terms to us,
or at all, including, without limitation, to fund our current and
future preclinical studies and clinical trials and the success,
timing and cost of our drug development program and our ongoing or
future preclinical studies and clinical trials, including, without
limitation, the possibility of unfavorable new clinical and
preclinical data and additional analyses of existing data, that the
risks that prior clinical and preclinical results may not be
replicated, and risks associated with the current coronavirus
pandemic. Forward-looking statements speak only as of the date of
this press release, and we undertake no obligation to review or
update any forward-looking statement except as may be required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221115005085/en/
Investor Inquiries
MAIA Biotechnology Joseph McGuire Chief Financial Officer
jmcguire@maiabiotech.com 904-228-2603
ICR Westwicke Stephanie Carrington
Stephanie.carrington@westwicke.com 646-277-1282
Media Inquiries
ICR Westwicke Sean Leous Sean.leous@westwicke.com
646-866-4012
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Maia Biotechnology (AMEX:MAIA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024